Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects
NCT07476157Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Apr 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-118 in chronic heart failure (CHF) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma concentration-time curve during dosing interval and Maximum concentration of drug in plasma. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
AD-118
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT07476157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476157.